Comparison · NCT03480022-d1217fe3
Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: 10% Body Weight Loss From Baseline
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Liraglutide Pen Injector (Saxenda) vs Placebo Liraglutide Pen Injector: 10% Body Weight Loss From Baseline. Trial comparisons, record NCT03480022-d1217fe3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03480022-d1217fe3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.295 | 0.182 | 0.442 | wilson | |
| Risk in group 2 | 0.087 | 0.0242 | 0.268 | wilson | |
| Risk difference, group 1 minus group 2 | 0.208 | -0.00536 | 0.368 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.4 | 0.837 | 13.8 | log | |
| Odds ratio, group 1 over group 2 | 4.4 | 0.899 | 21.6 | log | |
| Number needed to treat, for one more participant with the outcome on Liraglutide Pen Injector (Saxenda) than on Placebo Liraglutide Pen Injector | 4.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Liraglutide Pen Injector (Saxenda) | Start injection liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg liraglutide SQ daily~Liraglutide Pen Injector \[Saxenda\]: daily sc injection of liraglutide with final dose of 3mg daily | 13 | 44 | OG000 |
| Group 2 | Placebo Liraglutide Pen Injector | Start injection of placebo liraglutide 0.6 mg subcutaneously (SC) 1week daily (QD), step up to 1.2 mg SC QD for 1week, to 1.8 mg SC QD for 1 week, 2.4 mg SC QD for 1week, to a final dose of 3.0 mg placebo liraglutide SQ daily~Placebo Liraglutide Pen Injector: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo | 2 | 23 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- 10% Body Weight Loss From Baseline
- Description
- Frequency of patients with at least 10% reduction in body weight from baseline
- Time frame
- 32 weeks of treatment
- Population
Source ClinicalTrials.gov
Trial
- Title
- Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
- NCT number
- NCT03480022
- Phases
- PHASE3
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Interventions
- Liraglutide Pen Injector [Saxenda], Placebo Liraglutide Pen Injector
- Lead sponsor
- Woman's
- Results first posted
- 2021-06-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03480022?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03480022-d1217fe3